Roche gets Chinese approval for Tecentriq plus chemotherapy to treat ES-SCLC

This article was originally published here

Tecentriq is a monoclonal antibody designed to bind with PD-L1 protein that is expressed on tumour cells and tumour-infiltrating immune cells, restricting its interactions with both PD-1 and

The post Roche gets Chinese approval for Tecentriq plus chemotherapy to treat ES-SCLC appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply